Trial Profile
A Phase I, Open Label Study of the Safety, Tolerance and Assessment of HE3286 on Insulin Sensitivity and Hepatic Glucose Production When Administered Orally to Obese Insulin-Resistant Adult Subjects for 28 Days.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs NE 3107 (Primary)
- Indications Insulin resistance
- Focus Adverse reactions
- 08 Mar 2011 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 08 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.